Skip to main content

What the FDA labels say about taking them together

Atorvastatin and siltuximab

Siltuximab's FDA label of August 27, 2024 names atorvastatin in its drug interactions section; the atorvastatin labels PlainMeds reads (2) do not name siltuximab. The siltuximab label: “Exercise caution when SYLVANT is co-administered with CYP3A4 substrate drugs where a decrease in effectiveness would be undesirable.”

Check it at the source: the atorvastatin FDA label on DailyMed (effective April 15, 2024, Viatris Specialty LLC); the siltuximab FDA label on DailyMed (effective August 27, 2024).

What does the atorvastatin label say about siltuximab?

Atorvastatin's label (effective April 15, 2024) and its 1 other brand-application label do not name siltuximab in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Lipitor), NDA020702 (Upjohn), as published by Viatris Specialty LLC, effective April 15, 2024 (SPL set a60cc18b-0631-4cf0-b021-9f52224ece65), via openFDA; the full label on DailyMed

What does the siltuximab label say about atorvastatin?

Siltuximab label, drug interactions

Exercise caution when SYLVANT is co-administered with CYP3A4 substrate drugs where a decrease in effectiveness would be undesirable (e.g., oral contraceptives, lovastatin, atorvastatin).

Source: FDA drug label (Sylvant), Recordati Rare Diseases, Inc., effective August 27, 2024 (SPL set 8d663642-f52e-49c0-a023-2da083fdfc0b), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

59Atorvastatin generic labelers
0Siltuximab generic labelers
AtorvastatinSiltuximab
Labeled forHigh cholesterol, Angina, High triglycerides, Heart attack and coronary artery diseasen/a
Boxed warningNoNo
Pharmacy cost (NADAC)$0.0228 per tablet 10 mg tabletn/a
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?